Safe Indoor Temperature Limit for Fans
Fan Use During Extreme Heat: Safe Thermal Limits
1 other identifier
interventional
10
1 country
1
Brief Summary
Extreme heat events are a significant global threat to health and wellbeing, and result in more morbidity and mortality than all other natural disasters combined. Thus, a key priority is identifying effective and accessible heat resilience solutions to protect individuals from the potentially fatal consequences of heat stress. Within a range of ambient conditions, a fan has been recognized a low-cost heat resilience solution. However, when ambient temperatures exceed skin temperatures (e.g., above 35°C), a fan will incur greater dry heat gain which may be counterbalanced with evaporation of sweat from the skin surface. However, at a critical indoor temperature, the rate of heat gain will exceed the rate of evaporation resulting in net heat gain. The critical indoor temperature has yet to be determined. The purpose of this present study is to identify the indoor temperature at which a fan results in greater cardiovascular and thermal strain relative to still air in young adults using a simulated heat wave scenario of a warming room.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2024
CompletedFirst Submitted
Initial submission to the registry
September 3, 2024
CompletedFirst Posted
Study publicly available on registry
September 5, 2024
CompletedSeptember 19, 2024
September 1, 2024
3 months
September 3, 2024
September 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Blood Pressure
Measured with an electrocardiogram-gated automated cuff
At baseline (e.g. 0 minutes), and every 10 minutes of exposure up to 180 minutes
Rate Pressure Product
At baseline (e.g. 0 minutes), and every 10 minutes of exposure up to 180 minutes
Heart Rate
Measured with a 3-lead electrocardiogram
At baseline (e.g. 0 minutes), and every minute for the 180 minute experimental trial
Skin Temperature
Measured at 4 skin locations (chest, arm, thigh, and calf) using wireless iButtons affixed to the skin with surgical tape
At baseline (e.g. 0 minutes), and every minute for the 180 minute experimental trial
Core Temperature
rectal temperature measured with a pediatric grade thermistor probe
At baseline (e.g. 0 minutes), and every minute for the 180 minute experimental trial
Whole-Body Sweat Rate
Net difference in body mass (pre versus post) using a balance scale placed below the chair of the participant
At baseline (e.g. 0 minutes), and every minute for the 180 minute experimental trial
Secondary Outcomes (2)
Thermal Sensation
At baseline (e.g. 0 minutes), and every 10 minutes for the 180 minute experimental trial
Thermal comfort
Assessed at baseline (e.g. 0 minutes), and every 10 minutes for the 180 minute experimental trial
Study Arms (2)
Still air
PLACEBO COMPARATORstill air condition with no supplemental air flow
Electric fan
EXPERIMENTALForce air flow with a 46 cm 3-blade fan positioned 1.2 m anterior to the participants chest
Interventions
Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
Eligibility Criteria
You may qualify if:
- Body mass index less than 30
- male or female
- ability to tolerate hot environments for a prolonged period (e.g. \>2 h)
You may not qualify if:
- Any respiratory disease
- Any cardiovascular disease, including hypertension
- Diabetes
- not currently on any medication (except oral contraceptives)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lakehead University
Thunder Bay, Ontario, P7B 5E1, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Nicholas Ravanelli, PhD
National University of Singapore
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
September 3, 2024
First Posted
September 5, 2024
Study Start
January 20, 2024
Primary Completion
April 30, 2024
Study Completion
April 30, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Following publication
- Access Criteria
- Anyone will be allowed to access the data supporting the findings through the Open Science Framework Repository.
All deidentified participant data supporting the findings of this study will be made freely available on the Open Science Framework Repository.